share_log

Evercore ISI Group Downgrades BELLUS Health to In-Line, Lowers Price Target to $14.75

Benzinga ·  Apr 18, 2023 09:38

Evercore ISI Group analyst Josh Schimmer downgrades BELLUS Health (NASDAQ:BLU) from Outperform to In-Line and lowers the price target from $24 to $14.75.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment